ACR20, American College of Rheumatology 20% improvement in response; ACR50, American College of Rheumatology 50% improvement in response; ACR70, American College of Rheumatology 70% improvement in ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today announced positive data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of Sotyktu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback